A business with a wide economic moat, a Piotroski score of 9 out of 9, and 16% margins trades at a forward multiple of 6.1x with a PEG of 0.05 — implying the market is deeply discounting a franchise with durable return characteristics; the setup is held back by three earnings misses in the last four quarters and a sole-product revenue base that amplifies any execution stumble.
Thesis pillars
- Wide Moat Bargain Valuation→Stable
- Single Product Sole Source Concentration→Stable
- Earnings Miss Pattern Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Harmony Biosciences Holdings, I (HRMY) Stock Analysis
Temporary headwind edge
Healthcare · Biotechnology
Wait for pullback to $32.58. Weak momentum; also recent C-suite change — blocks BUY_NOW at $34.41. Engine's entry $32.58 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers.
Harmony Biosciences commercializes WAKIX (pitolisant), the only FDA-approved non-scheduled narcolepsy treatment, cleared for excessive daytime sleepiness and cataplexy in adult and pediatric patients. WAKIX generated $868.5 million in net product revenue in fiscal 2025 from a... Read more
Wait for pullback to $32.58. Weak momentum; also recent C-suite change — blocks BUY_NOW at $34.41. Engine's entry $32.58 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 54% MoS with quality 8.8. | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Score 7.1/10, high confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news boost earnings 0.80, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated Nov 5, 2026Recent Developments — Harmony Biosciences Holdings, I
Latest news
- NEWS HRMY|Harmony Biosciences Holdings Inc|Price:34.415|Chg%:-2.605 - TradingKey — TradingKey Nov 5, 2026 neutral
- NEWS Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming — Finviz Nov 4, 2026 negative
- NEWS Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates - Yahoo Finance — Yahoo Finance Nov 4, 2026 negative
- NEWS Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It (NASDAQ:HRMY) - Seeking Alpha — Seeking Alpha Oct 21, 2026 neutral
Latest item Nov 5, 2026 · Generated 2026-11-05T11:29:00Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductWAKIX10-K Item 1A: 'we expect the sales of WAKIX to generate substantially all of our revenue for the foreseeable future'
- HIGHSuppliersole-source suppliers and manufacturers10-K Item 1A: 'We rely completely on third parties to manufacture and distribute our supply of WAKIX and our product candidates, including certain sole-source suppliers and manufacturers'
- HIGHSupplierBioprojet license10-K Item 1A: 'We rely on our license agreements with Bioprojet to provide rights to the core intellectual property relating to pitolisant'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02MEDIUMCFO Sandip Kapadia stepped down effective April 14, 2026 to pursue other career opportunities. Glenn Reicin appointed as successor CFO effective the same day.SEC filing →
- 2026-04-02Item 5.02LOWPeter Anastasiou appointed Senior EVP and COO effective April 2, 2026. In connection with appointment, resigned as Class III board director effective same date. No disagreement with Company or Board cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·3 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $32.58. Weak momentum; also recent C-suite change — blocks BUY_NOW at $34.41. Engine's entry $32.58 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 54% MoS with quality 8.8. | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Target $41.83 (+21.5%), stop $30.30 (−13.6%), A.R:R 2.0:1. Score 7.1/10, high confidence.
Take-profit target: $41.83 (+21.6% upside). Target $41.83 (+21.5%), stop $30.30 (−13.6%), A.R:R 2.0:1. Stop-loss: $30.30.
Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers; Consecutive earnings misses (3).
Harmony Biosciences Holdings, I trades at a P/E of 11.4 (forward 4.9). TrendMatrix value score: 8.9/10. Verdict: Buy (Wait for Entry).
18 analysts rate HRMY, with a consensus score of 3.9/5. 12 analysts publish price targets averaging $48.
What does Harmony Biosciences Holdings, I do?Harmony Biosciences commercializes WAKIX (pitolisant), the only FDA-approved non-scheduled narcolepsy treatment,...
Harmony Biosciences commercializes WAKIX (pitolisant), the only FDA-approved non-scheduled narcolepsy treatment, cleared for excessive daytime sleepiness and cataplexy in adult and pediatric patients. WAKIX generated $868.5 million in net product revenue in fiscal 2025 from a U.S. narcolepsy market valued at approximately $3.1 billion. The company holds an exclusive U.S. license from Bioprojet and relies entirely on third-party contract manufacturers, including certain sole-source suppliers.